Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.

Authors: Zapatero-Solana, Elisabet, Ding, Yan, Pulliam, Nicholas, de Dios, Alfonso, Ortiz-Ruiz, Maria Jesus, Lallena, María José

Source: International Journal of Molecular Sciences; Mar2025, Vol. 26 Issue 6, p2643, 18p

Subject Terms: CYCLIN-dependent kinase inhibitors, FULVESTRANT, BREAST cancer, HORMONE therapy, CELL cycle

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015–2019)

Authors: Sánchez-Martínez, Concepción, Lallena, María José, Sanfeliciano, Sonia Gutiérrez, de Dios, Alfonso

Source: In Bioorganic & Medicinal Chemistry Letters 15 October 2019 29(20)

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Authors: Schaer, David A., Beckmann, Richard P., Dempsey, Jack A., Huber, Lysiane, Forest, Amelie, Amaladas, Nelusha, Li, Yanxia, Wang, Ying Cindy, Rasmussen, Erik R., Chin, Darin, Capen, Andrew, Carpenito, Carmine, Staschke, Kirk A., Chung, Linda A., Litchfield, Lacey M., Merzoug, Farhana F., Gong, Xueqian, Iversen, Philip W., Buchanan, Sean, de Dios, Alfonso, Novosiadly, Ruslan D., Kalos, Michael

Source: In Cell Reports 13 March 2018 22(11):2978-2994

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Authors: Gong, Xueqian, Litchfield, Lacey M., Webster, Yue, Chio, Li-Chun, Wong, Swee Seong, Stewart, Trent R., Dowless, Michele, Dempsey, Jack, Zeng, Yi, Torres, Raquel, Boehnke, Karsten, Mur, Cecilia, Marugán, Carlos, Baquero, Carmen, Yu, Chunping, Bray, Steven M., Wulur, Isabella H., Bi, Chen, Chu, Shaoyou, Qian, Hui-Rong, Iversen, Philip W., Merzoug, Farhana F., Ye, Xiang S., Reinhard, Christoph, De Dios, Alfonso, Du, Jian, Caldwell, Charles W., Lallena, María José, Beckmann, Richard P., Buchanan, Sean G.

Source: In Cancer Cell 11 December 2017 32(6):761-776

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Authors: Raub, Thomas J. ^*, Wishart, Graham N., Kulanthaivel, Palaniappan, Staton, Brian A. ¹, Ajamie, Rose T., Sawada, Geri A., Gelbert, Lawrence M. ², Shannon, Harlan E. ², Sanchez-Martinez, Concepcion, De Dios, Alfonso

Source: In Drug Metabolism and Disposition September 2015 43(9):1360-1371

Cyclin dependent kinase (CDK) inhibitors as anticancer drugs

Authors: Sánchez-Martínez, Concepción, Gelbert, Lawrence M., Lallena, María José, de Dios, Alfonso

Source: In Bioorganic & Medicinal Chemistry Letters 1 September 2015 25(17):3420-3435

Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy.

Authors: Gharbi, Severine Isabelle, Pelletier, Laura A., Espada, Alfonso, Gutiérrez, Jesus, Sanfeliciano, Sonia Maria Gutiérrez, Rauch, Charles T., Ganado, Maria Patricia, Baquero, Carmen, Zapatero, Elisabet, Zhang, Aiping, Benach, Jordi, Russell, Anna-Maria, Cano, Leticia, Gomez, Sandra, Broughton, Howard, Pulliam, Nicholas, Perez, Carmen Maria, Torres, Raquel, Debets, Marjoke F., de Dios, Alfonso

Source: NPJ Breast Cancer; 11/29/2022, Vol. 8 Issue 1, p1-11, 11p

Kinase inhibitors

Kinase inhibitors

Kinase inhibitors

KINASE INHIBITORS

Pyrazole-isoquinoline urea derivatives as p38 kinase inhibitors

Pyrazole-Isoquinoline Urea Derivatives as P38 Kinase Inhibitors

Kinase Inhibitors

Kinase Inhibitors

Benzimidazoles and benzothiazoles as inhibitors of map kinase

Thiophene-and thiazolesulfonamides as antineoplastic agents

Thiophene-and thiazolesulfonamides as antineoplastic agents

Prodrugs of excitatory amino acids

Benzimidazoles and benzothiazoles as inhibitors of map kinase